ArticleJournal of industrial microbiology & biotechnology2018
Synthetic biology advances and applications in the biotechnology industry: a perspective.
Article in Journal of industrial microbiology & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Engineering a genetic construct to express soluble proteins tethered to the cell membrane.Bioscience reports · 2026Article
- Synthetic transcriptional repression systems in plants.Plant cell reports · 2026Review
- SUPER: Upcycling Genetic Parts for Precise Gene Expression Control, Leakage Minimization, and Genetic Circuit Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Safe Meat, Smart Science: Biotechnology's Role in Antibiotic Residue Removal.Antibiotics (Basel, Switzerland) · 2025Review
- AI-directed gene fusing prolongs the evolutionary half-life of synthetic gene circuits.Science advances · 2025Article
- Automated and Programmable Cell-Free Systems for Scalable Synthetic Biology with a Focus on Biofoundry Integration.Journal of microbiology and biotechnology · 2025Review
- Genome mining reveals the distribution of biosynthetic gene clusters in Alternaria and related fungal taxa within the family Pleosporaceae.BMC genomics · 2025Article
- Considerations for Domestication of Novel Strains of Filamentous Fungi.ACS synthetic biology · 2025Review
- Bioengineering hybrid artificial life.Frontiers in bioinformatics · 2025Review
- Bacteriophage Challenges in Industrial Processes: A Historical Unveiling and Future Outlook.Pathogens (Basel, Switzerland) · 2024Review
- Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.Medical oncology (Northwood, London, England) · 2024Review
- From competition to cure: the development of live biotherapeutic products for anticancer therapy in the iGEM competition.Frontiers in bioengineering and biotechnology · 2024Review
- Synthetic Gene Circuits Combining CRISPR Interference and CRISPR Activation inACS synthetic biology · 2023Article
- Metabolic engineering ofSynthetic and systems biotechnology · 2023Article
- Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies.ACS synthetic biology · 2023Review
- The Application of Metagenomics to Study Microbial Communities and Develop Desirable Traits in Fermented Foods.Foods (Basel, Switzerland) · 2022Review
- Engineering ofInternational journal of molecular sciences · 2022Article
- Precursor Quantitation Methods for Next Generation Food Production.Frontiers in bioengineering and biotechnology · 2022Review
- Bibliometric analysis of artificial intelligence for biotechnology and applied microbiology: Exploring research hotspots and frontiers.Frontiers in bioengineering and biotechnology · 2022Review
- Discovery of a gene cluster for the biosynthesis of novel cyclic peptide compound, KK-1, inFrontiers in fungal biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic biology is a logical extension of what has been called recombinant DNA (rDNA) technology or genetic engineering since the 1970s. As rDNA technology has been the driver for the development of a thriving biotechnology industry today, starting with the commercialization of biosynthetic human insulin in the early 1980s, synthetic biology has the potential to take the industry to new heights in the coming years. Synthetic biology advances have been driven by dramatic cost reductions in DNA sequencing and DNA synthesis; by the development of sophisticated tools for genome editing, such as CRISPR/Cas9; and by advances in informatics, computational tools, and infrastructure to facilitate and scale analysis and design. Synthetic biology approaches have already been applied to the metabolic engineering of microorganisms for the production of industrially important chemicals and for the engineering of human cells to treat medical disorders. It also shows great promise to accelerate the discovery and development of novel secondary metabolites from microorganisms through traditional, engineered, and combinatorial biosynthesis. We anticipate that synthetic biology will continue to have broadening impacts on the biotechnology industry to address ongoing issues of human health, world food supply, renewable energy, and industrial chemicals and enzymes.
Indexed as
Identifiers
29915997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.